Tumor Biology

, Volume 36, Issue 4, pp 3009–3015 | Cite as

Preliminary screening of differentially expressed genes involved in methyl-CpG-binding protein 2 gene-mediated proliferation in human osteosarcoma cells

  • Gang Meng
  • Yi Li
  • YangFan lv
  • Huanzi Dai
  • Xi Zhang
  • Qiao-Nan GuoEmail author
Research Article


Methyl-CpG-binding protein 2 (MeCP2) is essential in human brain development and has been linked to several cancer types and neuro-developmental disorders. This study aims to screen the MeCP2 related differentially expressed genes and discover the therapeutic targets for osteosarcoma. CCK8 assay was used to detect the proliferation and SaOS2 and U2OS cells. Apoptosis of cells was detected by flow cytometry analysis that monitored Annexin V-APC/7-DD binding and 7-ADD uptake simultaneously. Denaturing formaldehyde agarose gel electrophoresis was employed to examine the quality of total RNA 18S and 28S units. Gene chip technique was utilized to discover the differentially expressed genes correlated with MeCP2 gene. Differential gene screening criteria were used to screen the changed genes. The gene up-regulation or down-regulation more than 1.5 times was regarded as significant differential expression genes. The CCK8 results indicated that the cell proliferation of MeCP2 silencing cells (LV-MeCP2-RNAi) was significantly decreased compared to non-silenced cells (LV-MeCP2-RNAi-CN) (P < 0.05). MeCP2 silencing could also induce significant apoptosis compared to non-silenced cells (P < 0.05); 107 expression changed genes were screened from a total of 49,395 transcripts. Among the total 107 transcripts, 34 transcripts were up-regulated and 73 transcripts were down-regulated. There were five significant differentially expressed genes, including IGFBP4, HOXC8, LMO4, MDK, and CTGF, which correlated with the MeCP2 gene. The methylation frequency of CpG in IGFBP4 gene could achieve 55 %. In conclusion, the differentially expressed IGFBP4, HOXC8, LMO4, MDK, and CTGF genes may be involved in MeCP2 gene-mediated proliferation and apoptosis in osteosarcoma cells.


Methyl-CpG-binding protein 2 Osteosarcoma Proliferation Differentially expressed genes 



This work was supported by a grant from the National Natural Science Foundation of China (81001198 and 81372864).

Conflicts of interest



  1. 1.
    Miao JL, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumor Biol. 2013;34(4):2093–8.CrossRefGoogle Scholar
  2. 2.
    Stiller CA. International patterns of cancer incidence in adolescents. Cancer Treat Rev. 2007;33(7):631–45.CrossRefPubMedGoogle Scholar
  3. 3.
    Futamura N, Nishida Y, Urakawa H, Kozawa E, Ikuta K, Hamada S, et al. EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma. Tumor Biol. 2014;35(6):5159–65.CrossRefGoogle Scholar
  4. 4.
    Ando K, Heymann MF, Stresing V, Mori K, Redini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancer (Basel). 2013;5(2):591–616.CrossRefGoogle Scholar
  5. 5.
    Jones PA. DNA methylation and cancer. Oncogene. 2002;21(35):5358–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Siedlecki P, Zielenkiewicz P. Mammalian DNA methyltransferases. Acta Biochim Pol. 2006;53(2):245–56.PubMedGoogle Scholar
  7. 7.
    Silva TD, Vidigal VM, Felipe AV, de Lima JM, Neto RA, Saad SS, et al. DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol Lett. 2013;6(6):1687–92.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005;97(20):1498–506.CrossRefPubMedGoogle Scholar
  9. 9.
    Yaqinuddin A, Abbas F, Nagvi SZ, Bashir MU, Qazi R, Qureshi SA. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotype. Biosci Rep. 2008;28(6):319–26.CrossRefPubMedGoogle Scholar
  10. 10.
    Yi JM, Dhir M, Guzzetta AA, Lacobuzio-Donahue CA, Heo K, Yang KM, et al. DNA methylation biomarker candidates for early detection of colon cancer. Tumor Biol. 2012;33(2):363–72.CrossRefGoogle Scholar
  11. 11.
    Keller S, Angrisano T, Florio E, Pero R, Decaussin-Petrucci M, Troncone G, et al. DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. Oncol Lett. 2013;6(1):86–90.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Muotri AR, Marchetto MC, Coufal NG, Oefner R, Yeo G, Nakashima K. L1 retrotransposition in neurons is modulated by MeCP2. Nature. 2010;468(7322):443–6.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Schena M, Shalon D, Davis RW. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270(5235):467–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang Y, Zhang L, Zhang G, Li S, Duan J, Cheng J, et al. Osteosarcoma metastasis: prospective role of ezrin. Tumor Biol. 2014;35(6):5055–9.CrossRefGoogle Scholar
  15. 15.
    Chen TW, Li HP, Lee C, Gan RC, Huang PJ, Wu TH, et al. ChIP seek, a web-based analysis tool for ChIP data. BMC Genomics. 2014;15(1):539.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Xu K, Liu XN, Zhang HB, An N, Wang Y, Zhang ZC, et al. Replication-defective HSV-1 effectively targets trigeminal ganglion and inhibits viral pathopoiesis by mediating interferon gamma expression in SH-SY5Y cells. J Mol Neurosci. 2014;53(1):78–86.CrossRefPubMedGoogle Scholar
  17. 17.
    Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22(3):326–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Squillaro T, Alessio N, Cipollaro M, Renieri A, Giordano A, Galderisi U. Partial silencing of methyl cytosine protein binding 2 (MECP2) in mesenchymal stem cells induces senescence with an increase in damaged DNA. FASEB J. 2010;24(5):1593–603.CrossRefPubMedGoogle Scholar
  19. 19.
    Mirza S, Sharma G, Parshad R, Gupta SD, Pandya P, Ralhan R. Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J Breast Cancer. 2013;16(1):23–31.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Do SI, Ko E, Kang SY, Lee JE, Nam SJ, Cho EY, et al. Aberrant DNA methylation of integrin alpha-4 inhuman breast cancer. Tumor Biol. 2014;35(7):7079–84.CrossRefGoogle Scholar
  21. 21.
    Grigoras D, Pirtea L, Ceausu RA. Endothelial progenitor cells contribute to the development of ovarian carcinoma tumor blood vessels. Oncol Lett. 2014;7(5):1511–4.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Zhao LY, Zhang J, Guo B, Yang J, Han J, Zhao XG, et al. MeCP2 promotes cell proliferation by activating ERK1/2 and inhibiting p38 activity in human hepatocellular carcinoma HEPG2 cells. Cell Mol Biol Suppl. 2013;59:OL1876–81.Google Scholar
  23. 23.
    Bernard D, Gil J, Dumont P, Rizzo S, Monte D, Quatannens B, et al. The methyl-CpG-binding protein MeCP2 is required for prostate cancer cell growth. Oncogene. 2006;25(9):1358–66.CrossRefPubMedGoogle Scholar
  24. 24.
    Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3–34.PubMedGoogle Scholar
  25. 25.
    Lewinski A, Marcinkowska M, Brzezianska E, Jeziorowska A, Wloch J, Brzezinski J. Expression of insulin-like growth factor I gene and of genes for IGF-binding proteins 1, 2, 3, 4 (IGFBP-1-IGFBP-4) in non-neoplastic human thyroid cells and in certain human thyroid cancers. Effect of exogenous IGF-I on this expression. Endocr Res. 2004;30(1):47–59.CrossRefPubMedGoogle Scholar
  26. 26.
    Ryan AJ, Napoletano S, Fitzpatrick PA, Currid CA, O’Sullivan NC, Harmey JH. Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumor growth in a murine model of breast cancer. Br J Cancer. 2009;101(2):278–86.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Alami Y, Castronovo V, Belotti D, Flagiello D, Clausse N. HOXC5 and HOXC8 expression are selectively turned on in human cervical cancer cells compared to normal keratinocytes. Biochem Biophys Res Commun. 1999;257(3):738–45.CrossRefPubMedGoogle Scholar
  28. 28.
    Waltregny D, Alami Y, Clausse N, de Leval J, Castronovo V. Overexpression of the homeobox gene HOXC8 in human prostate cancer correlations with loss of tumor differentiation. Prostate. 2002;50(3):162–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Li Y, Chao F, Huang B, Liu D, Kim J, Huang S. HOXC8 promotes breast tumorigenesis by transcriptionally facilitating cadherin-11 expression. Oncotarget. 2014;5(9):2596–607.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yu J, Ohuchida K, Nakata K, Mizumoto K, Cui L, Fujita H, et al. LIM only 4 is overexpressed in late stage pancreas cancer. Mol Cancer. 2008;7(1):93.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Comelison R, et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 2002;62(5):1256–60.PubMedGoogle Scholar
  32. 32.
    Cui L, Xie R, Dang S, Zhang Q, Mao S, Chen J, et al. NOV promoted the growth and migration of pancreatic cancer cells. Tumor Biol. 2014;35(4):3195–201.CrossRefGoogle Scholar
  33. 33.
    Tomizawa M, Yu L, Wada A, Tamaoki T, Kadomatsu. A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the alpha-fetoprotein promoter. Br J Cancer. 2003;89(6):1086–90.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Erguven M, Bilir A, Yazihan N, Korkmaz S, Aktas E, Ovalioglu C, et al. Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine. Oncol Lett. 2012;3(1):200–8.PubMedGoogle Scholar
  35. 35.
    Hao H, Maeda Y, Fukazawa T, Yamatsuji T, Takaoka M, Bao XH, et al. Inhibition of the growth factor MDK/midkine by a novel molecule compound to treat non-small cell lung cancer. PLoS One. 2013;8(8):e71093.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Zhou ZQ, Zao WH, Xie JJ, Lin J, Shen ZY, Zhang QY, et al. Expression and prognostic significance of THBS1, cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer. 2009;9(1):291.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 2009;69(3):775–84.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Jia XQ, Cheng HQ, Li H, Zhu Y, Li YH, Feng ZQ, et al. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo. Chin Med J (Engl). 2011;124(22):3794–9.Google Scholar
  39. 39.
    Wang L, Chen Z, Wang Y, Chang D, Su L, Guo Y, et al. WWTR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer. Tumor Biol. 2014;35(1):463–8.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Gang Meng
    • 1
  • Yi Li
    • 2
  • YangFan lv
    • 1
  • Huanzi Dai
    • 3
  • Xi Zhang
    • 1
  • Qiao-Nan Guo
    • 1
    Email author
  1. 1.Department of Pathology, Xinqiao HospitalThird Military Medical UniversityChongqingChina
  2. 2.Department of OncologyKunming General Hospital of Chengdu Military CommandKunmingChina
  3. 3.Department of Nephrology, Daping HospitalThird Military Medical UniversityChongqingChina

Personalised recommendations